Recognized with 2018 Business Innovation Award by MBOT
TORONTO, November 19, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it has been recognized with the 2018 Business Innovation Award by the Mississauga Board of Trade (MBOT).
The award was provided to Microbix at the MBOT Business Awards of Excellence event the evening of November 15. The 2018 Business Innovation Award was in recognition of Microbix’s innovations in making native antigens and quality assessment products, its accelerating sales growth, and its emphasis on international markets. Microbix was chosen by the MBOT judging committee from among a field of 70 nominees across eleven awards categories.
Microbix’s native antigens are used for the development or manufacturing of tests to detect the level of patients’ antibodies to an infectious disease. Results of such tests provide medically-important information concerning exposure to, or immunity against, the relevant pathogens. Microbix provides the needed antigens to more than 100 makers of such medical tests. Microbix’s quality assessment products (QAPs™) contain native antigens and nucleic-acids, and have been engineered to support quality assessment of each crucial step of complex medical tests.
Established in 1961, the MBOT serves and represents the interest of businesses of all sizes and sectors in the Mississauga community. Located adjacent to Toronto, Mississauga is Canada’s sixth largest city and the third largest in Ontario. Mississauga has a population of nearly 800,000, with over 50,000 businesses that employ 440,000 people – including the Canadian headquarters of 60 “Fortune 500” companies.
Cameron Groome, CEO and President of Microbix, commented on the MBOT award, “We greatly appreciate this recognition from our peers in the Mississauga business community. We are proud of everyone on our team of 80 skilled business and scientific professionals and thank them for their diligent work. We likewise thank all other stakeholders that support Microbix, including our customers, suppliers, financial partners, the City of Mississauga and the MBOT.”
About Microbix Biosystems
Microbix Biosystems Inc. specializes in the development of proprietary biological and technology solutions for human health and well-being. The Company manufactures a wide range of critical biological materials for the global diagnostics industry, notably antigens used in immunoassays or quality assessment and proficiency testing products. The Company also applies its biological expertise and technology platforms to create other innovative products and technologies. Currently it is working to commercialize two such proprietary products, (1) Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots and (2) LumiSort™ cell-sorting, a technology platform for ultra-rapid and efficient sorting of somatic cells that can be used to enrich cell populations of interest, such as in sexing semen. Established in 1988, Microbix is a publicly traded company, listed on the Toronto Stock Exchange and headquartered in Mississauga, Ontario, Canada.
This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, management’s discussion of new products being introduced or exhibited, industry needs or trends, financial results or the outlook for the business, the risks associated with its financial results and stability, its biologicals business, development projects such as those referenced herein, operations in foreign jurisdictions, engineering and construction generally, production (including control over costs, quality, quantity and timeliness of delivery of products), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward looking information is inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company’s judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.
Please visit www.sedar.com for recent Microbix filings.
For further information, please contact:
Cameron L. Groome, CEO
Jim Currie, CFO
Deborah Honig, Investor Relations – Adelaide Capital Markets
(647) 203-8793 firstname.lastname@example.org